AbbVie reached a voluntary, decade‑long agreement with the U.S. administration to invest $100 billion in U.S.-based research, development and manufacturing while expanding direct‑to‑patient programs and patient access initiatives. The pact includes pricing concessions for certain programs and tariff exemptions from the administration; detailed terms remain confidential. The agreement frames industry‑government collaboration on domestic manufacturing and access as an alternative to statutory price controls. AbbVie said the deal addresses multiple presidential drug‑pricing priorities and will expand programs for high-profile medicines. The pact may set a precedent for industry tradeoffs between investment pledges and regulatory or procurement incentives.